Reuters logo
BRIEF-Sigma Pharmaceuticals says FY underlying NPAT up 13.0 pct to $66.9 mln
March 22, 2017 / 9:38 PM / 6 months ago

BRIEF-Sigma Pharmaceuticals says FY underlying NPAT up 13.0 pct to $66.9 mln

March 23 (Reuters) - Sigma Pharmaceuticals Ltd:

* FY underlying npat up 13.0% to $66.9 million

* “we confirm our previous guidance of at least 5pct underlying ebit growth for fy18”

* FY revenue $4.4 billion, up 26.2pct

* Proposed final dividend of 3.0 cents per share Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below